Overview
Exploit Technologies commercialises A*STAR’s technologies into industrial applications through licensing and research collaboration projects with the industry partners.
LICENSING OF TECHNOLOGIES & IPs
In collaborating with Exploit Technologies, the industry players and businesses can benefit from innovative technologies, commercialisation of technology funding, research collaborations and licensing of technology offers.
Companies can save significant costs on executing its own research and development and thereby lower its risks on R&D investment. Instead, by collaborating with Exploit Technologies, the companies can benefit from licensing proof-of-concept technologies and integrate them into their products and processes.
In tandem with A*STAR’s mission to promote research and the broad dissemination of technology to industry to promote economic activity, Exploit Technologies adopts a flexible approach to licensing for successful collaborations with the industries to maximise adoption of the technology.
Exploit Technologies boosts of two dedicated commercialisation teams in the biomedical sciences and science engineering field.
The Biomedical Sciences Division actively seeks commercialisation opportunities for the following technologies:
- Biopharmaceuticals
- Medical devices
- Nanotechnology
- Bioinformatics
- Genomics and proteomics
- Molecular and cell biology
The Science & Engineering Commercialisation Division actively seeks commercialisation opportunities for the following technologies:
- Chemicals & Materials
- Communications
- General Engineering
- Information Technology
- Manufacturing Technology
- Mechanical Devices
RESEARCH COLLABORATION AGREEMENT (COMMERCIALISATION)
Exploit Technologies also collaborates with large multinational companies to jointly translate technology innovation into industry applications where the industry player could actively participate and fund the development into applications where it has large market potential and takes a license from Exploit Technologies.
|
